TD-0212 (TFA)
- CAS No.
- 1073549-11-7
- Chemical Name:
- TD-0212 (TFA)
- Synonyms
- TD-0212 (TFA);TD0212 TFA,TD 0212 TFA
- CBNumber:
- CB45848836
- Molecular Formula:
- C30H35F4N3O6S
- Molecular Weight:
- 641.68
- MDL Number:
- MOL File:
- 1073549-11-7.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| TD-0212 (TFA) | YSB54911 | 1mg | $806.06 |
| TD-0212 (TFA) | YSB54911 | 5mg | $2278 |
| TD-0212 (TFA) | YSB54911 | 10mg | $3644.8 |
| TD-0212 (TFA) | YSB54911 | 25mg | $6834 |
| TD-0212 (TFA) | YSB54911 | 50mg | $10934.5 |
TD-0212 (TFA) price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | YSB54911 | TD-0212 (TFA) | 1073549-11-7 | 1mg | $806.06 | 2026-06-05 | Buy |
| Biosynth | YSB54911 | TD-0212 (TFA) | 1073549-11-7 | 5mg | $2278 | 2026-06-05 | Buy |
| Biosynth | YSB54911 | TD-0212 (TFA) | 1073549-11-7 | 10mg | $3644.8 | 2026-06-05 | Buy |
| Biosynth | YSB54911 | TD-0212 (TFA) | 1073549-11-7 | 25mg | $6834 | 2026-06-05 | Buy |
| Biosynth | YSB54911 | TD-0212 (TFA) | 1073549-11-7 | 50mg | $10934.5 | 2026-06-05 | Buy |
TD-0212 (TFA) Chemical Properties,Uses,Production
Description
TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP[1].
TD-0212 provides the enhanced activity of dual AT1/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition[1].
TD-0212 produces blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors in models of renin-dependent and -independent hypertension[1].
Uses
TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP[1].
in vivo
TD-0212 produces blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors in models of renin-dependent and -independent hypertension[1].
IC 50
AT1 Receptor
References
[1]. McKinnell RM, et al. Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI). ACS Med Chem Lett. 2018 Dec 3;10(1):86-91.
TD-0212 (TFA) Preparation Products And Raw materials
Raw materials
Preparation Products
TD-0212 (TFA) Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 | sales@chemegen.com | China | 11123 | 58 |
| Shanghai hongqu biomedical technology co. LTD | 88888888888 | hongquchem@qq.com | China | 5123 | 58 |
| RD International Technology Co., Limited | 18024082417 | market@ubiochem.com | China | 9831 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Biosynth Biological Technology (Suzhou) Co Ltd | -- | sales@biosynth.com | China | 6032 | 58 |
